Ц.Билэгтсайхан
Loading...
Товч нэр
Ц.Билэгтсайхан
Бүтэн нэр
Цолмон Билэгтсайхан
Латин нэр
Tsolmon Bilegtsaikhan
Албан тушаал
Проректор
Эрдмийн цол
Дэд профессор
Боловсролын зэрэг
Доктор (Ph.D)
ORCID
Scopus Author ID
5 results
Now showing 1 - 5 of 5
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Additional file 1 of Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019–2022)(Figshare (United Kingdom), 2025-01-01) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D. ;Batsaikhan, PurevsurenSuuri, Bujinlkham - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pneumococcal carriage and disease in adults hospitalised with community-acquired pneumonia in Mongolia: prospective pneumonia surveillance program (2019-2022)(2025-11) ;Mungun, Tuya ;Ulziibayar, Munkhchuluun ;Nguyen, Cattram D ;Batsaikhan, PurevsurenSuuri, BujinlkhamBACKGROUND: Streptococcus pneumoniae is an important cause of pneumonia in older adults, however, serotyping and indirect impact information from low and middle-income countries is lacking. Mongolia has a childhood 13-valent pneumococcal conjugate vaccine (PCV13) program, but no adult pneumococcal vaccination program. We describe pneumococcal carriage rates, disease and serotype distribution among adults hospitalised with pneumonia, and explore changes over the COVID-19 pandemic period. METHODS: Adults (≥ 18 years) hospitalised with clinical pneumonia were enrolled over 3 years (March 2019-February 2022) into a prospective pneumonia surveillance program. Nasopharyngeal swabs were tested to detect pneumococci using lytA qPCR and molecular serotyping by DNA microarray and metagenomics. Pneumococcal pneumonia was identified using serotype-specific urinary antigen detection and BinaxNOW® assays. Pneumococcal carriage and pneumonia prevalence were assessed over the COVID-19 period with log-binomial regression used to estimate prevalence and adjusted prevalence ratios (pre- versus early- and late-COVID-19 periods). RESULTS: Of 3,178 pneumonia cases, S. pneumoniae was identified in 12.1% (333/2,759) of swabs and 8.6% (253/2,925) of urine samples. PCV13 serotype carriage prevalence was 3.1% (82/2,663) and non-PCV13 serotype carriage prevalence 5.7% (152/2,663). In the late-COVID-19 period, pneumococcal carriage prevalence was reduced by 66% (aPR 0.34, 95%CI 0.25-0.46) and pneumococcal pneumonia by 82% (aPR 0.18, 95%CI 0.12-0.27) compared with the pre-COVID-19 transmission period. CONCLUSION: Despite paediatric vaccination with high coverage, we identified some residual PCV13 serotypes with predominance of non-PCV13 serotypes carried and causing disease in adults. Direct adult vaccination which targets these serotypes will potentially reduce disease in adults in Mongolia. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of childhood 13-valent pneumococcal conjugate vaccine introduction on adult pneumonia hospitalisations in Mongolia: a time series analysis(2024-03) ;Fagerli, Kirsten ;Ulziibayar, Munkhchuluun ;Suuri, Bujinlkham ;Luvsantseren, DashtserenNarangerel, DorjBACKGROUND: Few studies have assessed the potential indirect effects of childhood pneumococcal conjugate vaccine (PCV) programs on the adult pneumonia burden in resource-limited settings. We evaluated the impact of childhood PCV13 immunisation on adult all-cause pneumonia following a phased program introduction from 2016. METHODS: We conducted a time-series analysis to assess changes in pneumonia hospitalisation incidence at four district hospitals in Mongolia. Adults (≥18 years) that met the clinical case definition for all-cause pneumonia were enrolled. A negative binomial mixed-effects model was used to assess the impact of PCV13 introduction on monthly counts of pneumonia admissions from January 2015-February 2022. We also performed a restricted analysis excluding the COVID-19 pandemic period. All models were stratified by age and assessed separately. Additional analyses assessed the robustness of our findings. FINDINGS: The average annual incidence of all-cause pneumonia hospitalisation was highest in adults 65+ years (62.81 per 10,000 population) and declined with decreasing age. After adjusting for the COVID-19 pandemic period, we found that rates of pneumonia hospitalisation remained largely unchanged over time. We did not observe a reduction in pneumonia hospitalisation in any age group. Results from restricted and sensitivity analyses were comparable to the primary results, finding limited evidence of a reduced pneumonia burden. INTERPRETATION: We did not find evidence of indirect protection against all-cause pneumonia in adults following childhood PCV13 introduction. Direct pneumococcal vaccination and other interventions should be considered to reduce burden of pneumonia among older adults. FUNDING: Pfizer clinical research collaboration agreement (contract number: WI236621).Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia(2026-01) ;Simkiss, Amy ;Ulziibayar, Munkhchuluun ;Batsaikhan, Purevsuren ;Suuri, BujinlkhamLuvsantseren, DashtserenBACKGROUND: Limited research has focused on risk factors for community acquired pneumonia (CAP) in adults in low-middle income countries (LMICs). Mongolia has high rates of CAP hospitalisations with extreme winter temperatures and significant air pollution. We aimed to examine risk factors for severe CAP among hospitalised adults aged ≥ 18 years in Mongolia. METHODS: Adults hospitalised with clinical CAP were enrolled over three years (2019–2022) into a prospective CAP surveillance program in four district hospitals in the capital city, Ulaanbaatar. Participants had clinical information and risk factors collected using a case report form. Nasopharyngeal swabs were collected and tested for Streptococcus pneumoniae (the pneumococcus), influenza and respiratory syncytial virus, while collected urine was tested for the pneumococcus. From 2020 only patients with a negative SARS-CoV-2 test were enrolled in the study. Severe CAP was defined as clinical CAP with intensive care unit admission or ≥ 2 severity signs (confusion, hypotension, tachypnoea or hypoxaemia). Multivariable logistic regression was used to derive adjusted risk factor estimates. RESULTS: Overall, 3178 participants met the CAP study case definition and 10.1% had severe CAP. Pneumococcal carriage (aOR:2.67; 95% CI:1.88–3.79; p < 0.001), pneumococcal serotype-specific urine antigen detection positivity (aOR:1.69; 95% CI:1.11–2.57; p = 0.01), hospital admission within the last year (aOR:1.73; 95% CI:1.26–2.37; p = 0.001), underlying medical conditions (aOR:1.96; 95% CI:1.39–2.76; p < 0.001), cigarette smoking (aOR:1.53; 95% CI:1.08–2.16; p = 0.01) and alcohol intake (aOR:2.19; 95% CI:1.49–3.22; p < 0.001), were identified as risk factors for severe CAP on multivariable analysis. CONCLUSION: We identified key risk factors for severe CAP in hospitalised adults in urban Mongolia. If resources are limited, this data could be used to prioritise groups for vaccinations, alongside public health policies to decrease tobacco smoking and alcohol consumption.Scopus© Citations 1
